4359-77-7

Upstream product

• 99115-96-5 3-ethyl-4-hydroxy-2-butanone 
• 39877-66-2 3-(dimethylamino-methyl)-pentan-2-one 
• 60535-61-7 2-ethyl-N,N,N-trimethyl-3-oxobutan-1-aminium iodide 
• 7553-56-2 iodine 
• 107-87-9 2-Pentanone 
• 23074-36-4 2-bromobutene 
• 78191-00-1 N-Methoxy-N-methylacetamide 
• 210359-35-6 2-(2-methyl-1,3-dioxolan-2-yl)butan-1-ol 
• 51756-08-2 methyl 2-ethyl-3-oxobutanoate 
• 1015170-68-9 4-acetoxy-3-ethyl-2-butanone 
• 51756-12-8 (2-ethyl-2-methoxycarbonyl-3-oxo-butyl)-trimethyl-ammonium; iodide 

Downstream Products

• 3586-58-1 2-methylenebutyric acid 
• 755760-40-8 3-hydroxy-3-hydroxymethyl-pentan-2-one 
• 25409-09-0 3-ethyl-but-3-en-2-one-(2,4-dinitro-phenylhydrazone) 
• 5648-02-2 3-Methylen-pentanon-(2)-semicarbazon 
• 91968-27-3 6-Acetyl-4-ethyl-3-methyl-cyclohex-2-en-1-on 
• 565-60-6 (3R)-(+)-3-methylpentan-2-ol 
• 57968-72-6 -3-methylpentan-2-one 
• 17257-82-8 3,4-epoxy-3-ethyl- 2-Butanone 
• 886224-12-0 3-ethyl-12-(toluene-4-sulfonyl)-3,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-one 
• 886224-20-0 [3-ethyl-12-(toluene-4-sulfonyl)-3,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-ylidene]acetic acid methyl ester 
• 223105-98-4 (R)-1-((S)-2-Ethyl-oxiranyl)-ethanol 
• 223106-03-4 1-((S)-2-Ethyl-oxiranyl)-ethanone 
• 103358-95-8 5-ethyl-6-methyl-hept-5-en-2-one 
• 1246832-76-7 C₂₇H₃₂N₂O₄S 

Relevant academic research and scientific papers

MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS

The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.

Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators

Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory depression. Accordingly, there is a longstanding interest in the development of new opioid analgesics with improved therapeutic profiles. The alkaloids of the Southeast Asian plant Mitragyna speciosa, represented by the prototypical member mitragynine, are an unusual class of opioid receptor modulators with distinct pharmacological properties. Here we describe the first receptor-level functional characterization of mitragynine and related natural alkaloids at the human mu-, kappa-, and delta-opioid receptors. These results show that mitragynine and the oxidized analogue 7-hydroxymitragynine, are partial agonists of the human mu-opioid receptor and competitive antagonists at the kappa- and delta-opioid receptors. We also show that mitragynine and 7-hydroxymitragynine are G-protein-biased agonists of the mu-opioid receptor, which do not recruit β-arrestin following receptor activation. Therefore, the Mitragyna alkaloid scaffold represents a novel framework for the development of functionally biased opioid modulators, which may exhibit improved therapeutic profiles. Also presented is an enantioselective total synthesis of both (-)-mitragynine and its unnatural enantiomer, (+)-mitragynine, employing a proline-catalyzed Mannich-Michael reaction sequence as the key transformation. Pharmacological evaluation of (+)-mitragynine revealed its much weaker opioid activity. Likewise, the intermediates and chemical transformations developed in the total synthesis allowed the elucidation of previously unexplored structure-activity relationships (SAR) within the Mitragyna scaffold. Molecular docking studies, in combination with the observed chemical SAR, suggest that Mitragyna alkaloids adopt a binding pose at the mu-opioid receptor that is distinct from that of classical opioids.

Enantioselective formal aza-Diels-Alder reactions of enones with cyclic imines catalyzed by primary aminothioureas

A highly enantio- and diastereoselective synthesis of indolo- and benzoquinolizidine compounds has been developed through the formal aza-Diels-Alder reaction of enones with cyclic imines. This transformation is catalyzed by a new bifunctional primary aminothiourea that achieves simultaneous activation of both the enone and imine reaction components.

SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS

This invention concerns sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1), wherein the symbols have the meanings given in the description.